Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023

IRVINE, CA, August 8, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15^th, 2023.

Josh Riggs, CEO of Oncocyte, will be meeting 1×1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for the conference with their Needham representative.

About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.  For more information, visit https://oncocyte.com/

VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com

SOURCE: Oncocyte

The post Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference first appeared on Prism Media Wire.